Virax Biolabs Group Limited
Virax Biolabs Group Limited (VRAX) Stock Competitors & Peer Comparison
See (VRAX) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| VRAX | $0.19 | +13.85% | 954.8K | -0.18 | -$1.22 | N/A |
| VRTX | $450.08 | +1.56% | 113.4B | 29.12 | $15.33 | N/A |
| REGN | $775.88 | +3.55% | 80.3B | 18.64 | $41.46 | +0.46% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $736.26 | +4.54% | 45.2B | 37.28 | $19.59 | N/A |
| ALNY | $329.75 | +4.32% | 43.9B | 142.63 | $2.32 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| INSM | $164.02 | +6.98% | 35.2B | -25.43 | -$6.43 | N/A |
| UTHR | $593.50 | +0.87% | 26B | 21.27 | $27.87 | N/A |
| BNTX | $89.56 | +5.06% | 22.3B | -16.40 | -$5.42 | N/A |
Stock Comparison
VRAX vs VRTX Comparison April 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 954.8K. In comparison, VRTX has a market cap of 113.4B. Regarding current trading prices, VRAX is priced at $0.19, while VRTX trades at $450.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.18, whereas VRTX's P/E ratio is 29.12. In terms of profitability, VRAX's ROE is -1.03%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, VRAX is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check VRTX's competition here
VRAX vs REGN Comparison April 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 954.8K. In comparison, REGN has a market cap of 80.3B. Regarding current trading prices, VRAX is priced at $0.19, while REGN trades at $775.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.18, whereas REGN's P/E ratio is 18.64. In terms of profitability, VRAX's ROE is -1.03%, compared to REGN's ROE of +0.15%. Regarding short-term risk, VRAX is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check REGN's competition here
VRAX vs VRNA Comparison April 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 954.8K. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, VRAX is priced at $0.19, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.18, whereas VRNA's P/E ratio is -102.80. In terms of profitability, VRAX's ROE is -1.03%, compared to VRNA's ROE of -0.30%. Regarding short-term risk, VRAX is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check VRNA's competition here
VRAX vs ARGX Comparison April 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 954.8K. In comparison, ARGX has a market cap of 45.2B. Regarding current trading prices, VRAX is priced at $0.19, while ARGX trades at $736.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.18, whereas ARGX's P/E ratio is 37.28. In terms of profitability, VRAX's ROE is -1.03%, compared to ARGX's ROE of +0.34%. Regarding short-term risk, VRAX is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check ARGX's competition here
VRAX vs ALNY Comparison April 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 954.8K. In comparison, ALNY has a market cap of 43.9B. Regarding current trading prices, VRAX is priced at $0.19, while ALNY trades at $329.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.18, whereas ALNY's P/E ratio is 142.63. In terms of profitability, VRAX's ROE is -1.03%, compared to ALNY's ROE of +0.90%. Regarding short-term risk, VRAX is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check ALNY's competition here
VRAX vs SGEN Comparison April 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 954.8K. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, VRAX is priced at $0.19, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.18, whereas SGEN's P/E ratio is -57.19. In terms of profitability, VRAX's ROE is -1.03%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, VRAX is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check SGEN's competition here
VRAX vs INSM Comparison April 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 954.8K. In comparison, INSM has a market cap of 35.2B. Regarding current trading prices, VRAX is priced at $0.19, while INSM trades at $164.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.18, whereas INSM's P/E ratio is -25.43. In terms of profitability, VRAX's ROE is -1.03%, compared to INSM's ROE of -1.68%. Regarding short-term risk, VRAX is more volatile compared to INSM. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check INSM's competition here
VRAX vs UTHR Comparison April 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 954.8K. In comparison, UTHR has a market cap of 26B. Regarding current trading prices, VRAX is priced at $0.19, while UTHR trades at $593.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.18, whereas UTHR's P/E ratio is 21.27. In terms of profitability, VRAX's ROE is -1.03%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, VRAX is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check UTHR's competition here
VRAX vs BNTX Comparison April 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 954.8K. In comparison, BNTX has a market cap of 22.3B. Regarding current trading prices, VRAX is priced at $0.19, while BNTX trades at $89.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.18, whereas BNTX's P/E ratio is -16.40. In terms of profitability, VRAX's ROE is -1.03%, compared to BNTX's ROE of -0.06%. Regarding short-term risk, VRAX is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check BNTX's competition here
VRAX vs RPRX Comparison April 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 954.8K. In comparison, RPRX has a market cap of 20.6B. Regarding current trading prices, VRAX is priced at $0.19, while RPRX trades at $48.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.18, whereas RPRX's P/E ratio is 26.95. In terms of profitability, VRAX's ROE is -1.03%, compared to RPRX's ROE of +0.12%. Regarding short-term risk, VRAX is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check RPRX's competition here
VRAX vs BGNE Comparison April 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 954.8K. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, VRAX is priced at $0.19, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.18, whereas BGNE's P/E ratio is -22.55. In terms of profitability, VRAX's ROE is -1.03%, compared to BGNE's ROE of +0.07%. Regarding short-term risk, VRAX is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check BGNE's competition here
VRAX vs MRNA Comparison April 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 954.8K. In comparison, MRNA has a market cap of 20.1B. Regarding current trading prices, VRAX is priced at $0.19, while MRNA trades at $51.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.18, whereas MRNA's P/E ratio is -7.00. In terms of profitability, VRAX's ROE is -1.03%, compared to MRNA's ROE of -0.30%. Regarding short-term risk, VRAX is more volatile compared to MRNA. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check MRNA's competition here
VRAX vs ROIV Comparison April 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 954.8K. In comparison, ROIV has a market cap of 19.8B. Regarding current trading prices, VRAX is priced at $0.19, while ROIV trades at $27.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.18, whereas ROIV's P/E ratio is -23.68. In terms of profitability, VRAX's ROE is -1.03%, compared to ROIV's ROE of -0.18%. Regarding short-term risk, VRAX is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check ROIV's competition here
VRAX vs RVMD Comparison April 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 954.8K. In comparison, RVMD has a market cap of 19.3B. Regarding current trading prices, VRAX is priced at $0.19, while RVMD trades at $98.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.18, whereas RVMD's P/E ratio is -16.34. In terms of profitability, VRAX's ROE is -1.03%, compared to RVMD's ROE of -0.63%. Regarding short-term risk, VRAX is more volatile compared to RVMD. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check RVMD's competition here
VRAX vs DNA-WT Comparison April 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 954.8K. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, VRAX is priced at $0.19, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.18, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, VRAX's ROE is -1.03%, compared to DNA-WT's ROE of -0.54%. Regarding short-term risk, VRAX is less volatile compared to DNA-WT. This indicates potentially lower risk in terms of short-term price fluctuations for VRAX.Check DNA-WT's competition here
VRAX vs INCY Comparison April 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 954.8K. In comparison, INCY has a market cap of 18.7B. Regarding current trading prices, VRAX is priced at $0.19, while INCY trades at $94.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.18, whereas INCY's P/E ratio is 14.68. In terms of profitability, VRAX's ROE is -1.03%, compared to INCY's ROE of +0.29%. Regarding short-term risk, VRAX is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check INCY's competition here
VRAX vs GMAB Comparison April 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 954.8K. In comparison, GMAB has a market cap of 16.5B. Regarding current trading prices, VRAX is priced at $0.19, while GMAB trades at $27.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.18, whereas GMAB's P/E ratio is 17.42. In terms of profitability, VRAX's ROE is -1.03%, compared to GMAB's ROE of +0.11%. Regarding short-term risk, VRAX is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check GMAB's competition here
VRAX vs BBIO Comparison April 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 954.8K. In comparison, BBIO has a market cap of 14.4B. Regarding current trading prices, VRAX is priced at $0.19, while BBIO trades at $74.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.18, whereas BBIO's P/E ratio is -19.65. In terms of profitability, VRAX's ROE is -1.03%, compared to BBIO's ROE of +0.39%. Regarding short-term risk, VRAX is more volatile compared to BBIO. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check BBIO's competition here
VRAX vs SMMT Comparison April 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 954.8K. In comparison, SMMT has a market cap of 14.1B. Regarding current trading prices, VRAX is priced at $0.19, while SMMT trades at $19.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.18, whereas SMMT's P/E ratio is -13.17. In terms of profitability, VRAX's ROE is -1.03%, compared to SMMT's ROE of -2.97%. Regarding short-term risk, VRAX is more volatile compared to SMMT. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check SMMT's competition here
VRAX vs ASND Comparison April 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 954.8K. In comparison, ASND has a market cap of 14B. Regarding current trading prices, VRAX is priced at $0.19, while ASND trades at $230.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.18, whereas ASND's P/E ratio is -52.70. In terms of profitability, VRAX's ROE is -1.03%, compared to ASND's ROE of +1.28%. Regarding short-term risk, VRAX is more volatile compared to ASND. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check ASND's competition here
VRAX vs KRTX Comparison April 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 954.8K. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, VRAX is priced at $0.19, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.18, whereas KRTX's P/E ratio is -28.09. In terms of profitability, VRAX's ROE is -1.03%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, VRAX is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check KRTX's competition here
VRAX vs IONS Comparison April 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 954.8K. In comparison, IONS has a market cap of 12.4B. Regarding current trading prices, VRAX is priced at $0.19, while IONS trades at $75.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.18, whereas IONS's P/E ratio is -31.55. In terms of profitability, VRAX's ROE is -1.03%, compared to IONS's ROE of -0.69%. Regarding short-term risk, VRAX is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check IONS's competition here
VRAX vs MDGL Comparison April 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 954.8K. In comparison, MDGL has a market cap of 12B. Regarding current trading prices, VRAX is priced at $0.19, while MDGL trades at $530.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.18, whereas MDGL's P/E ratio is -40.67. In terms of profitability, VRAX's ROE is -1.03%, compared to MDGL's ROE of -0.44%. Regarding short-term risk, VRAX is more volatile compared to MDGL. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check MDGL's competition here
VRAX vs JAZZ Comparison April 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 954.8K. In comparison, JAZZ has a market cap of 11.6B. Regarding current trading prices, VRAX is priced at $0.19, while JAZZ trades at $190.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.18, whereas JAZZ's P/E ratio is -32.37. In terms of profitability, VRAX's ROE is -1.03%, compared to JAZZ's ROE of -0.09%. Regarding short-term risk, VRAX is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check JAZZ's competition here
VRAX vs EXEL Comparison April 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 954.8K. In comparison, EXEL has a market cap of 11.5B. Regarding current trading prices, VRAX is priced at $0.19, while EXEL trades at $43.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.18, whereas EXEL's P/E ratio is 15.43. In terms of profitability, VRAX's ROE is -1.03%, compared to EXEL's ROE of +0.37%. Regarding short-term risk, VRAX is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check EXEL's competition here
VRAX vs RNAM Comparison April 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 954.8K. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, VRAX is priced at $0.19, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.18, whereas RNAM's P/E ratio is -17.39. In terms of profitability, VRAX's ROE is -1.03%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, VRAX is more volatile compared to RNAM. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check RNAM's competition here
VRAX vs BMRN Comparison April 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 954.8K. In comparison, BMRN has a market cap of 10.9B. Regarding current trading prices, VRAX is priced at $0.19, while BMRN trades at $56.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.18, whereas BMRN's P/E ratio is 31.38. In terms of profitability, VRAX's ROE is -1.03%, compared to BMRN's ROE of +0.06%. Regarding short-term risk, VRAX is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check BMRN's competition here
VRAX vs RXDX Comparison April 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 954.8K. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, VRAX is priced at $0.19, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.18, whereas RXDX's P/E ratio is -56.47. In terms of profitability, VRAX's ROE is -1.03%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, VRAX is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check RXDX's competition here
VRAX vs ARWR Comparison April 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 954.8K. In comparison, ARWR has a market cap of 8.8B. Regarding current trading prices, VRAX is priced at $0.19, while ARWR trades at $63.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.18, whereas ARWR's P/E ratio is 39.19. In terms of profitability, VRAX's ROE is -1.03%, compared to ARWR's ROE of +0.36%. Regarding short-term risk, VRAX is more volatile compared to ARWR. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check ARWR's competition here
VRAX vs IMGN Comparison April 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 954.8K. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, VRAX is priced at $0.19, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.18, whereas IMGN's P/E ratio is -111.55. In terms of profitability, VRAX's ROE is -1.03%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, VRAX is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check IMGN's competition here
VRAX vs AXSM Comparison April 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 954.8K. In comparison, AXSM has a market cap of 8.6B. Regarding current trading prices, VRAX is priced at $0.19, while AXSM trades at $172.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.18, whereas AXSM's P/E ratio is -46.05. In terms of profitability, VRAX's ROE is -1.03%, compared to AXSM's ROE of -2.54%. Regarding short-term risk, VRAX is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check AXSM's competition here
VRAX vs PCVX Comparison April 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 954.8K. In comparison, PCVX has a market cap of 8.4B. Regarding current trading prices, VRAX is priced at $0.19, while PCVX trades at $58.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.18, whereas PCVX's P/E ratio is -10.32. In terms of profitability, VRAX's ROE is -1.03%, compared to PCVX's ROE of -0.26%. Regarding short-term risk, VRAX is more volatile compared to PCVX. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check PCVX's competition here
VRAX vs BPMC Comparison April 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 954.8K. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, VRAX is priced at $0.19, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.18, whereas BPMC's P/E ratio is -51.58. In terms of profitability, VRAX's ROE is -1.03%, compared to BPMC's ROE of -0.15%. Regarding short-term risk, VRAX is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check BPMC's competition here
VRAX vs CERE Comparison April 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 954.8K. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, VRAX is priced at $0.19, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.18, whereas CERE's P/E ratio is -16.47. In terms of profitability, VRAX's ROE is -1.03%, compared to CERE's ROE of -0.72%. Regarding short-term risk, VRAX is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check CERE's competition here
VRAX vs TECH Comparison April 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 954.8K. In comparison, TECH has a market cap of 8.2B. Regarding current trading prices, VRAX is priced at $0.19, while TECH trades at $52.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.18, whereas TECH's P/E ratio is 98.60. In terms of profitability, VRAX's ROE is -1.03%, compared to TECH's ROE of +0.04%. Regarding short-term risk, VRAX is more volatile compared to TECH. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check TECH's competition here
VRAX vs CYTK Comparison April 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 954.8K. In comparison, CYTK has a market cap of 8.1B. Regarding current trading prices, VRAX is priced at $0.19, while CYTK trades at $67.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.18, whereas CYTK's P/E ratio is -10.08. In terms of profitability, VRAX's ROE is -1.03%, compared to CYTK's ROE of +1.73%. Regarding short-term risk, VRAX is more volatile compared to CYTK. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check CYTK's competition here
VRAX vs IBRX Comparison April 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 954.8K. In comparison, IBRX has a market cap of 7.9B. Regarding current trading prices, VRAX is priced at $0.19, while IBRX trades at $7.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.18, whereas IBRX's P/E ratio is -20.18. In terms of profitability, VRAX's ROE is -1.03%, compared to IBRX's ROE of +0.64%. Regarding short-term risk, VRAX is less volatile compared to IBRX. This indicates potentially lower risk in terms of short-term price fluctuations for VRAX.Check IBRX's competition here
VRAX vs HALO Comparison April 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 954.8K. In comparison, HALO has a market cap of 7.6B. Regarding current trading prices, VRAX is priced at $0.19, while HALO trades at $64.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.18, whereas HALO's P/E ratio is 25.25. In terms of profitability, VRAX's ROE is -1.03%, compared to HALO's ROE of +0.93%. Regarding short-term risk, VRAX is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check HALO's competition here
VRAX vs KRYS Comparison April 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 954.8K. In comparison, KRYS has a market cap of 7.6B. Regarding current trading prices, VRAX is priced at $0.19, while KRYS trades at $259.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.18, whereas KRYS's P/E ratio is 37.71. In terms of profitability, VRAX's ROE is -1.03%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, VRAX is more volatile compared to KRYS. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check KRYS's competition here
VRAX vs NUVL Comparison April 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 954.8K. In comparison, NUVL has a market cap of 7.5B. Regarding current trading prices, VRAX is priced at $0.19, while NUVL trades at $104.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.18, whereas NUVL's P/E ratio is -17.51. In terms of profitability, VRAX's ROE is -1.03%, compared to NUVL's ROE of -0.42%. Regarding short-term risk, VRAX is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check NUVL's competition here
VRAX vs MTSR Comparison April 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 954.8K. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, VRAX is priced at $0.19, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.18, whereas MTSR's P/E ratio is -23.58. In terms of profitability, VRAX's ROE is -1.03%, compared to MTSR's ROE of -0.80%. Regarding short-term risk, VRAX is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check MTSR's competition here
VRAX vs ABVX Comparison April 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 954.8K. In comparison, ABVX has a market cap of 7.3B. Regarding current trading prices, VRAX is priced at $0.19, while ABVX trades at $115.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.18, whereas ABVX's P/E ratio is -19.96. In terms of profitability, VRAX's ROE is -1.03%, compared to ABVX's ROE of -1.59%. Regarding short-term risk, VRAX is more volatile compared to ABVX. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check ABVX's competition here
VRAX vs MRUS Comparison April 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 954.8K. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, VRAX is priced at $0.19, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.18, whereas MRUS's P/E ratio is -17.05. In terms of profitability, VRAX's ROE is -1.03%, compared to MRUS's ROE of -0.51%. Regarding short-term risk, VRAX is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check MRUS's competition here
VRAX vs PRAX Comparison April 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 954.8K. In comparison, PRAX has a market cap of 6.8B. Regarding current trading prices, VRAX is priced at $0.19, while PRAX trades at $326.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.18, whereas PRAX's P/E ratio is -23.90. In terms of profitability, VRAX's ROE is -1.03%, compared to PRAX's ROE of -0.59%. Regarding short-term risk, VRAX is more volatile compared to PRAX. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check PRAX's competition here
VRAX vs KYMR Comparison April 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 954.8K. In comparison, KYMR has a market cap of 6.8B. Regarding current trading prices, VRAX is priced at $0.19, while KYMR trades at $84.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.18, whereas KYMR's P/E ratio is -22.57. In terms of profitability, VRAX's ROE is -1.03%, compared to KYMR's ROE of -0.29%. Regarding short-term risk, VRAX is more volatile compared to KYMR. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check KYMR's competition here
VRAX vs PTGX Comparison April 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 954.8K. In comparison, PTGX has a market cap of 6.7B. Regarding current trading prices, VRAX is priced at $0.19, while PTGX trades at $105.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.18, whereas PTGX's P/E ratio is -51.41. In terms of profitability, VRAX's ROE is -1.03%, compared to PTGX's ROE of -0.20%. Regarding short-term risk, VRAX is more volatile compared to PTGX. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check PTGX's competition here
VRAX vs ACLX Comparison April 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 954.8K. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, VRAX is priced at $0.19, while ACLX trades at $114.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.18, whereas ACLX's P/E ratio is -28.21. In terms of profitability, VRAX's ROE is -1.03%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, VRAX is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check ACLX's competition here
VRAX vs RETA Comparison April 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 954.8K. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, VRAX is priced at $0.19, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.18, whereas RETA's P/E ratio is -66.29. In terms of profitability, VRAX's ROE is -1.03%, compared to RETA's ROE of +0.47%. Regarding short-term risk, VRAX is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check RETA's competition here
VRAX vs BLTE Comparison April 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 954.8K. In comparison, BLTE has a market cap of 6.3B. Regarding current trading prices, VRAX is priced at $0.19, while BLTE trades at $164.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.18, whereas BLTE's P/E ratio is -69.02. In terms of profitability, VRAX's ROE is -1.03%, compared to BLTE's ROE of -0.43%. Regarding short-term risk, VRAX is more volatile compared to BLTE. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check BLTE's competition here
VRAX vs COGT Comparison April 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 954.8K. In comparison, COGT has a market cap of 6.2B. Regarding current trading prices, VRAX is priced at $0.19, while COGT trades at $34.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.18, whereas COGT's P/E ratio is -17.82. In terms of profitability, VRAX's ROE is -1.03%, compared to COGT's ROE of -1.00%. Regarding short-term risk, VRAX is less volatile compared to COGT. This indicates potentially lower risk in terms of short-term price fluctuations for VRAX.Check COGT's competition here
VRAX vs RYTM Comparison April 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 954.8K. In comparison, RYTM has a market cap of 5.9B. Regarding current trading prices, VRAX is priced at $0.19, while RYTM trades at $87.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.18, whereas RYTM's P/E ratio is -27.96. In terms of profitability, VRAX's ROE is -1.03%, compared to RYTM's ROE of -1.79%. Regarding short-term risk, VRAX is more volatile compared to RYTM. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check RYTM's competition here
VRAX vs ALKS Comparison April 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 954.8K. In comparison, ALKS has a market cap of 5.9B. Regarding current trading prices, VRAX is priced at $0.19, while ALKS trades at $35.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.18, whereas ALKS's P/E ratio is 24.75. In terms of profitability, VRAX's ROE is -1.03%, compared to ALKS's ROE of +0.14%. Regarding short-term risk, VRAX is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check ALKS's competition here
VRAX vs CGON Comparison April 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 954.8K. In comparison, CGON has a market cap of 5.7B. Regarding current trading prices, VRAX is priced at $0.19, while CGON trades at $67.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.18, whereas CGON's P/E ratio is -32.54. In terms of profitability, VRAX's ROE is -1.03%, compared to CGON's ROE of -0.23%. Regarding short-term risk, VRAX is more volatile compared to CGON. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check CGON's competition here
VRAX vs SRRK Comparison April 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 954.8K. In comparison, SRRK has a market cap of 5.6B. Regarding current trading prices, VRAX is priced at $0.19, while SRRK trades at $49.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.18, whereas SRRK's P/E ratio is -14.94. In terms of profitability, VRAX's ROE is -1.03%, compared to SRRK's ROE of -1.46%. Regarding short-term risk, VRAX is more volatile compared to SRRK. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check SRRK's competition here
VRAX vs PTCT Comparison April 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 954.8K. In comparison, PTCT has a market cap of 5.6B. Regarding current trading prices, VRAX is priced at $0.19, while PTCT trades at $68.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.18, whereas PTCT's P/E ratio is 7.94. In terms of profitability, VRAX's ROE is -1.03%, compared to PTCT's ROE of -3.62%. Regarding short-term risk, VRAX is more volatile compared to PTCT. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check PTCT's competition here
VRAX vs CDTX Comparison April 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 954.8K. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, VRAX is priced at $0.19, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.18, whereas CDTX's P/E ratio is -19.77. In terms of profitability, VRAX's ROE is -1.03%, compared to CDTX's ROE of -0.60%. Regarding short-term risk, VRAX is more volatile compared to CDTX. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check CDTX's competition here
VRAX vs ABCM Comparison April 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 954.8K. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, VRAX is priced at $0.19, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.18, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, VRAX's ROE is -1.03%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, VRAX is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check ABCM's competition here
VRAX vs CELC Comparison April 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 954.8K. In comparison, CELC has a market cap of 5.5B. Regarding current trading prices, VRAX is priced at $0.19, while CELC trades at $115.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.18, whereas CELC's P/E ratio is -30.12. In terms of profitability, VRAX's ROE is -1.03%, compared to CELC's ROE of -2.03%. Regarding short-term risk, VRAX is more volatile compared to CELC. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check CELC's competition here
VRAX vs ISEE Comparison April 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 954.8K. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, VRAX is priced at $0.19, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.18, whereas ISEE's P/E ratio is -22.44. In terms of profitability, VRAX's ROE is -1.03%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, VRAX is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check ISEE's competition here
VRAX vs FBIOX Comparison April 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 954.8K. In comparison, FBIOX has a market cap of 5.4B. Regarding current trading prices, VRAX is priced at $0.19, while FBIOX trades at $25.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.18, whereas FBIOX's P/E ratio is N/A. In terms of profitability, VRAX's ROE is -1.03%, compared to FBIOX's ROE of +0.00%. Regarding short-term risk, VRAX is more volatile compared to FBIOX. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check FBIOX's competition here
VRAX vs CNTA Comparison April 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 954.8K. In comparison, CNTA has a market cap of 5.3B. Regarding current trading prices, VRAX is priced at $0.19, while CNTA trades at $39.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.18, whereas CNTA's P/E ratio is -21.02. In terms of profitability, VRAX's ROE is -1.03%, compared to CNTA's ROE of -0.68%. Regarding short-term risk, VRAX is more volatile compared to CNTA. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check CNTA's competition here
VRAX vs TGTX Comparison April 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 954.8K. In comparison, TGTX has a market cap of 5.3B. Regarding current trading prices, VRAX is priced at $0.19, while TGTX trades at $33.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.18, whereas TGTX's P/E ratio is 11.99. In terms of profitability, VRAX's ROE is -1.03%, compared to TGTX's ROE of +1.01%. Regarding short-term risk, VRAX is more volatile compared to TGTX. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check TGTX's competition here
VRAX vs APLS Comparison April 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 954.8K. In comparison, APLS has a market cap of 5.1B. Regarding current trading prices, VRAX is priced at $0.19, while APLS trades at $40.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.18, whereas APLS's P/E ratio is 223.50. In terms of profitability, VRAX's ROE is -1.03%, compared to APLS's ROE of +0.08%. Regarding short-term risk, VRAX is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check APLS's competition here
VRAX vs IMVT Comparison April 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 954.8K. In comparison, IMVT has a market cap of 5.1B. Regarding current trading prices, VRAX is priced at $0.19, while IMVT trades at $25.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.18, whereas IMVT's P/E ratio is -9.30. In terms of profitability, VRAX's ROE is -1.03%, compared to IMVT's ROE of -0.66%. Regarding short-term risk, VRAX is more volatile compared to IMVT. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check IMVT's competition here
VRAX vs CAI Comparison April 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 954.8K. In comparison, CAI has a market cap of 5.1B. Regarding current trading prices, VRAX is priced at $0.19, while CAI trades at $18.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.18, whereas CAI's P/E ratio is -5.55. In terms of profitability, VRAX's ROE is -1.03%, compared to CAI's ROE of +0.25%. Regarding short-term risk, VRAX is more volatile compared to CAI. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check CAI's competition here
VRAX vs ERAS Comparison April 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 954.8K. In comparison, ERAS has a market cap of 5B. Regarding current trading prices, VRAX is priced at $0.19, while ERAS trades at $16.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.18, whereas ERAS's P/E ratio is -36.77. In terms of profitability, VRAX's ROE is -1.03%, compared to ERAS's ROE of -0.34%. Regarding short-term risk, VRAX is more volatile compared to ERAS. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check ERAS's competition here
VRAX vs TERN Comparison April 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 954.8K. In comparison, TERN has a market cap of 4.7B. Regarding current trading prices, VRAX is priced at $0.19, while TERN trades at $52.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.18, whereas TERN's P/E ratio is -51.69. In terms of profitability, VRAX's ROE is -1.03%, compared to TERN's ROE of -0.20%. Regarding short-term risk, VRAX is more volatile compared to TERN. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check TERN's competition here
VRAX vs APGE Comparison April 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 954.8K. In comparison, APGE has a market cap of 4.7B. Regarding current trading prices, VRAX is priced at $0.19, while APGE trades at $84.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.18, whereas APGE's P/E ratio is -19.95. In terms of profitability, VRAX's ROE is -1.03%, compared to APGE's ROE of -0.37%. Regarding short-term risk, VRAX is more volatile compared to APGE. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check APGE's competition here
VRAX vs MIRM Comparison April 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 954.8K. In comparison, MIRM has a market cap of 4.6B. Regarding current trading prices, VRAX is priced at $0.19, while MIRM trades at $96.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.18, whereas MIRM's P/E ratio is -196.55. In terms of profitability, VRAX's ROE is -1.03%, compared to MIRM's ROE of -0.09%. Regarding short-term risk, VRAX is more volatile compared to MIRM. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check MIRM's competition here
VRAX vs XENE Comparison April 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 954.8K. In comparison, XENE has a market cap of 4.6B. Regarding current trading prices, VRAX is priced at $0.19, while XENE trades at $58.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.18, whereas XENE's P/E ratio is -13.34. In terms of profitability, VRAX's ROE is -1.03%, compared to XENE's ROE of -0.56%. Regarding short-term risk, VRAX is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check XENE's competition here
VRAX vs CRSP Comparison April 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 954.8K. In comparison, CRSP has a market cap of 4.6B. Regarding current trading prices, VRAX is priced at $0.19, while CRSP trades at $48.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.18, whereas CRSP's P/E ratio is -7.35. In terms of profitability, VRAX's ROE is -1.03%, compared to CRSP's ROE of -0.32%. Regarding short-term risk, VRAX is more volatile compared to CRSP. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check CRSP's competition here
VRAX vs FOLD Comparison April 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 954.8K. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, VRAX is priced at $0.19, while FOLD trades at $14.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.18, whereas FOLD's P/E ratio is -160.67. In terms of profitability, VRAX's ROE is -1.03%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, VRAX is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check FOLD's competition here
VRAX vs AKRO Comparison April 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 954.8K. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, VRAX is priced at $0.19, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.18, whereas AKRO's P/E ratio is -14.57. In terms of profitability, VRAX's ROE is -1.03%, compared to AKRO's ROE of -0.31%. Regarding short-term risk, VRAX is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check AKRO's competition here
VRAX vs ALPN Comparison April 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 954.8K. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, VRAX is priced at $0.19, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.18, whereas ALPN's P/E ratio is -101.52. In terms of profitability, VRAX's ROE is -1.03%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, VRAX is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check ALPN's competition here
VRAX vs CORT Comparison April 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 954.8K. In comparison, CORT has a market cap of 4.3B. Regarding current trading prices, VRAX is priced at $0.19, while CORT trades at $41.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.18, whereas CORT's P/E ratio is 49.16. In terms of profitability, VRAX's ROE is -1.03%, compared to CORT's ROE of +0.15%. Regarding short-term risk, VRAX is less volatile compared to CORT. This indicates potentially lower risk in terms of short-term price fluctuations for VRAX.Check CORT's competition here
VRAX vs OPT Comparison April 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 954.8K. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, VRAX is priced at $0.19, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.18, whereas OPT's P/E ratio is -1.52. In terms of profitability, VRAX's ROE is -1.03%, compared to OPT's ROE of +0.88%. Regarding short-term risk, VRAX is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check OPT's competition here
VRAX vs MRTX Comparison April 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 954.8K. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, VRAX is priced at $0.19, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.18, whereas MRTX's P/E ratio is -4.82. In terms of profitability, VRAX's ROE is -1.03%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, VRAX is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check MRTX's competition here
VRAX vs LGND Comparison April 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 954.8K. In comparison, LGND has a market cap of 4B. Regarding current trading prices, VRAX is priced at $0.19, while LGND trades at $200.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.18, whereas LGND's P/E ratio is 32.62. In terms of profitability, VRAX's ROE is -1.03%, compared to LGND's ROE of +0.14%. Regarding short-term risk, VRAX is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check LGND's competition here
VRAX vs CRNX Comparison April 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 954.8K. In comparison, CRNX has a market cap of 3.8B. Regarding current trading prices, VRAX is priced at $0.19, while CRNX trades at $36.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.18, whereas CRNX's P/E ratio is -7.34. In terms of profitability, VRAX's ROE is -1.03%, compared to CRNX's ROE of -0.41%. Regarding short-term risk, VRAX is less volatile compared to CRNX. This indicates potentially lower risk in terms of short-term price fluctuations for VRAX.Check CRNX's competition here
VRAX vs ACAD Comparison April 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 954.8K. In comparison, ACAD has a market cap of 3.8B. Regarding current trading prices, VRAX is priced at $0.19, while ACAD trades at $22.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.18, whereas ACAD's P/E ratio is 9.68. In terms of profitability, VRAX's ROE is -1.03%, compared to ACAD's ROE of +0.42%. Regarding short-term risk, VRAX is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check ACAD's competition here
VRAX vs VKTX Comparison April 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 954.8K. In comparison, VKTX has a market cap of 3.8B. Regarding current trading prices, VRAX is priced at $0.19, while VKTX trades at $33.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.18, whereas VKTX's P/E ratio is -10.20. In terms of profitability, VRAX's ROE is -1.03%, compared to VKTX's ROE of -0.48%. Regarding short-term risk, VRAX is more volatile compared to VKTX. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check VKTX's competition here
VRAX vs RYZB Comparison April 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 954.8K. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, VRAX is priced at $0.19, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.18, whereas RYZB's P/E ratio is -57.86. In terms of profitability, VRAX's ROE is -1.03%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, VRAX is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check RYZB's competition here
VRAX vs CBAY Comparison April 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 954.8K. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, VRAX is priced at $0.19, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.18, whereas CBAY's P/E ratio is -32.81. In terms of profitability, VRAX's ROE is -1.03%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, VRAX is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check CBAY's competition here
VRAX vs NAMS Comparison April 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 954.8K. In comparison, NAMS has a market cap of 3.7B. Regarding current trading prices, VRAX is priced at $0.19, while NAMS trades at $32.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.18, whereas NAMS's P/E ratio is -18.61. In terms of profitability, VRAX's ROE is -1.03%, compared to NAMS's ROE of -0.27%. Regarding short-term risk, VRAX is less volatile compared to NAMS. This indicates potentially lower risk in terms of short-term price fluctuations for VRAX.Check NAMS's competition here
VRAX vs KNSA Comparison April 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 954.8K. In comparison, KNSA has a market cap of 3.6B. Regarding current trading prices, VRAX is priced at $0.19, while KNSA trades at $48.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.18, whereas KNSA's P/E ratio is 64.20. In terms of profitability, VRAX's ROE is -1.03%, compared to KNSA's ROE of +0.11%. Regarding short-term risk, VRAX is more volatile compared to KNSA. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check KNSA's competition here
VRAX vs SWTX Comparison April 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 954.8K. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, VRAX is priced at $0.19, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.18, whereas SWTX's P/E ratio is -13.78. In terms of profitability, VRAX's ROE is -1.03%, compared to SWTX's ROE of -0.45%. Regarding short-term risk, VRAX is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check SWTX's competition here
VRAX vs EWTX Comparison April 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 954.8K. In comparison, EWTX has a market cap of 3.4B. Regarding current trading prices, VRAX is priced at $0.19, while EWTX trades at $32.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.18, whereas EWTX's P/E ratio is -19.33. In terms of profitability, VRAX's ROE is -1.03%, compared to EWTX's ROE of -0.32%. Regarding short-term risk, VRAX is more volatile compared to EWTX. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check EWTX's competition here
VRAX vs LEGN Comparison April 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 954.8K. In comparison, LEGN has a market cap of 3.3B. Regarding current trading prices, VRAX is priced at $0.19, while LEGN trades at $18.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.18, whereas LEGN's P/E ratio is -11.17. In terms of profitability, VRAX's ROE is -1.03%, compared to LEGN's ROE of -0.29%. Regarding short-term risk, VRAX is less volatile compared to LEGN. This indicates potentially lower risk in terms of short-term price fluctuations for VRAX.Check LEGN's competition here
VRAX vs LQDA Comparison April 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 954.8K. In comparison, LQDA has a market cap of 3.3B. Regarding current trading prices, VRAX is priced at $0.19, while LQDA trades at $37.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.18, whereas LQDA's P/E ratio is -47.17. In terms of profitability, VRAX's ROE is -1.03%, compared to LQDA's ROE of -2.09%. Regarding short-term risk, VRAX is more volatile compared to LQDA. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check LQDA's competition here
VRAX vs TLX Comparison April 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 954.8K. In comparison, TLX has a market cap of 3.2B. Regarding current trading prices, VRAX is priced at $0.19, while TLX trades at $9.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.18, whereas TLX's P/E ratio is -478.50. In terms of profitability, VRAX's ROE is -1.03%, compared to TLX's ROE of -0.02%. Regarding short-term risk, VRAX is more volatile compared to TLX. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check TLX's competition here
VRAX vs DNTH Comparison April 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 954.8K. In comparison, DNTH has a market cap of 3.2B. Regarding current trading prices, VRAX is priced at $0.19, while DNTH trades at $85.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.18, whereas DNTH's P/E ratio is -19.98. In terms of profitability, VRAX's ROE is -1.03%, compared to DNTH's ROE of +0.00%. Regarding short-term risk, VRAX is more volatile compared to DNTH. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check DNTH's competition here
VRAX vs SYRE Comparison April 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 954.8K. In comparison, SYRE has a market cap of 3B. Regarding current trading prices, VRAX is priced at $0.19, while SYRE trades at $49.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.18, whereas SYRE's P/E ratio is -25.47. In terms of profitability, VRAX's ROE is -1.03%, compared to SYRE's ROE of -0.29%. Regarding short-term risk, VRAX is more volatile compared to SYRE. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check SYRE's competition here
VRAX vs DNLI Comparison April 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 954.8K. In comparison, DNLI has a market cap of 3B. Regarding current trading prices, VRAX is priced at $0.19, while DNLI trades at $19.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.18, whereas DNLI's P/E ratio is -6.46. In terms of profitability, VRAX's ROE is -1.03%, compared to DNLI's ROE of -0.50%. Regarding short-term risk, VRAX is more volatile compared to DNLI. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check DNLI's competition here
VRAX vs CPRX Comparison April 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 954.8K. In comparison, CPRX has a market cap of 3B. Regarding current trading prices, VRAX is priced at $0.19, while CPRX trades at $24.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.18, whereas CPRX's P/E ratio is 14.74. In terms of profitability, VRAX's ROE is -1.03%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, VRAX is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check CPRX's competition here
VRAX vs DYN Comparison April 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 954.8K. In comparison, DYN has a market cap of 3B. Regarding current trading prices, VRAX is priced at $0.19, while DYN trades at $18.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.18, whereas DYN's P/E ratio is -5.22. In terms of profitability, VRAX's ROE is -1.03%, compared to DYN's ROE of -0.61%. Regarding short-term risk, VRAX is more volatile compared to DYN. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check DYN's competition here
VRAX vs TARS Comparison April 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 954.8K. In comparison, TARS has a market cap of 3B. Regarding current trading prices, VRAX is priced at $0.19, while TARS trades at $70.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.18, whereas TARS's P/E ratio is -44.12. In terms of profitability, VRAX's ROE is -1.03%, compared to TARS's ROE of -0.20%. Regarding short-term risk, VRAX is more volatile compared to TARS. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check TARS's competition here
VRAX vs IDYA Comparison April 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 954.8K. In comparison, IDYA has a market cap of 2.9B. Regarding current trading prices, VRAX is priced at $0.19, while IDYA trades at $33.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.18, whereas IDYA's P/E ratio is -26.03. In terms of profitability, VRAX's ROE is -1.03%, compared to IDYA's ROE of -0.11%. Regarding short-term risk, VRAX is more volatile compared to IDYA. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check IDYA's competition here
VRAX vs ARQT Comparison April 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 954.8K. In comparison, ARQT has a market cap of 2.9B. Regarding current trading prices, VRAX is priced at $0.19, while ARQT trades at $23.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.18, whereas ARQT's P/E ratio is -181.23. In terms of profitability, VRAX's ROE is -1.03%, compared to ARQT's ROE of -0.10%. Regarding short-term risk, VRAX is more volatile compared to ARQT. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check ARQT's competition here
VRAX vs VERA Comparison April 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 954.8K. In comparison, VERA has a market cap of 2.9B. Regarding current trading prices, VRAX is priced at $0.19, while VERA trades at $41.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.18, whereas VERA's P/E ratio is -8.63. In terms of profitability, VRAX's ROE is -1.03%, compared to VERA's ROE of -0.60%. Regarding short-term risk, VRAX is less volatile compared to VERA. This indicates potentially lower risk in terms of short-term price fluctuations for VRAX.Check VERA's competition here